title: Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway.
abstract: To determine whether the systemic immune activation by CpG DNA could alter airway inflammation, we pretreated mice with either i.v. bacterial DNA (bDNA) or oligonucleotides with or without CpG motifs, exposed these mice to LPS by inhalation, and measured the inflammatory response systemically and in the lung immediately following LPS inhalation. Compared with non-CpG oligonucleotides, i. v. treatment with CpG oligonucleotides resulted in higher systemic concentrations of polymorphonuclear leukocytes, IL-10, and IL-12, but significantly reduced the concentration of total cells, polymorphonuclear leukocytes, TNF-alpha, and macrophage inflammatory protein-2 in the lavage fluid following LPS inhalation. The immunoprotective effect of CpG-containing oligonucleotides was dose-dependent and was most pronounced in mice pretreated between 2 and 4 h before the inhalation challenge, corresponding to the peak levels of serum cytokines. bDNA resulted in a similar immunoprotective effect, and methylation of the CpG motifs abolished the protective effect of CpG oligonucleotides. The protective effect of CpG oligonucleotides was observed in mice with either a disrupted IL-10 or IFN-gamma gene, but release of cytokines in the lung was increased, especially in the mice lacking IFN-gamma. In contrast, CpG DNA did not protect mice with a disrupted IL-12 gene against the LPS-induced cellular influx, even though CpG DNA reduced the release of TNF-alpha and macrophage inflammatory protein-2 in the lung. These findings indicate that CpG-containing oligonucleotides or bDNA are protected against LPS-induced cellular airway inflammation through an IL-12-dependent pathway, and that the pulmonary cytokine and cellular changes appear to be regulated independently.
authors.affiliation: Veterans Administration Medical Center, Iowa City 52242, USA. david_schwartz@uiowa.edu
authors.forename: D A
authors.initials: DA
authors.lastname: Schwartz
authors.forename: C L
authors.initials: CL
authors.lastname: Wohlford-Lenane
authors.forename: T J
authors.initials: TJ
authors.lastname: Quinn
authors.forename: A M
authors.initials: AM
authors.lastname: Krieg
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D018899:CpG Islands / Q000276:immunology*; D019175:DNA Methylation; D004269:DNA, Bacterial / Q000008:administration & dosage / Q000494:pharmacology*; D007249:Inflammation / Q000276:immunology / Q000517:prevention & control; D007275:Injections, Intravenous; D007371:Interferon-gamma / Q000172:deficiency / Q000235:genetics; D016753:Interleukin-10 / Q000172:deficiency / Q000235:genetics; D018664:Interleukin-12 / Q000097:blood / Q000502:physiology*; D008070:Lipopolysaccharides / Q000633:toxicity*; D008168:Lung / Q000276:immunology / Q000473:pathology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009841:Oligonucleotides / Q000008:administration & dosage / Q000138:chemical synthesis / Q000494:pharmacology*
chemical_list: D004269:DNA, Bacterial; D008070:Lipopolysaccharides; D009841:Oligonucleotides; D016753:Interleukin-10; D018664:Interleukin-12; D007371:Interferon-gamma